GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal critical care ...

– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 million loan agreement defers payment of principal and interest through June 2026 - – 60% increase in the number of hospital contracts since July 1, 2024, including U.S. Naval Hospital Guam – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or th ...

GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York on October 9th. If y ...

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.45 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.90%. A quarter ago, it was expected that this company would post a loss of $0.47 per share when it actually produced a loss of $0.36, delivering a surprise of 23.40%. Over the last four quarters, the company has surpass ...

GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer"), today announced the publication of its scientific article, "A safety evaluation ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Bank7 Corp. (BSVN) : This bank holding company for Bank7 has seen the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days. Okta, Inc. (OKTA) : This identity solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days. Silvercorp Metals Inc. (SVM) : This miner of mineral properties has seen the Zacks Consensus Estimate for its curren ...

Beyond Air, Inc. (XAIR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Therefore, the Zacks rating upgrade for Beyond Air basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Fundamentally speaking, rising earnings estimates and the consequent ra ...

GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company") a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer")), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond ...

GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company") a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer")), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond ...

Core Viewpoint - Beyond Air, Inc. (XAIR) has recently formed a hammer chart pattern, indicating a potential trend reversal after a downtrend, supported by rising optimism among analysts regarding future earnings [2][3]. Group 1: Technical Indicators - A hammer chart pattern has formed in XAIR's last trading session, suggesting that bulls may have gained control over the stock after a downtrend [2]. - The hammer pattern indicates a potential exhaustion of selling pressure, signaling a possible bottom for the stock [2]. Group 2: Fundamental Indicators - Over the last 30 days, the consensus EPS estimate for XAIR has increased by 30.2%, indicating that analysts expect better earnings than previously predicted [3]. - XAIR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [3]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the likelihood of a trend reversal [3].